136 related articles for article (PubMed ID: 3755714)
41. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
42. The repair of DNA damage induced in V79 mammalian cells by the nitroimidazole-aziridine, RSU-1069. Implications for radiosensitization.
Jenner TJ; O'Neill P; Crump PW; Fielden EM; Sapora O; Santodonato L
Biochem Pharmacol; 1991 Oct; 42(9):1705-10. PubMed ID: 1930296
[TBL] [Abstract][Full Text] [Related]
43. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
44. Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapy.
Bernstein M; Gutin PH; Deen DF; Weaver KA; Levin VA; Barcellos MH
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):487-90. PubMed ID: 7107372
[TBL] [Abstract][Full Text] [Related]
45. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
47. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
[TBL] [Abstract][Full Text] [Related]
48. Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors.
Ono K; Komuro C; Nishidai T; Shibamoto Y; Tsutsui K; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1986 Sep; 12(9):1661-6. PubMed ID: 3759592
[TBL] [Abstract][Full Text] [Related]
49. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
Chaplin DJ
Br J Cancer; 1986 Nov; 54(5):727-31. PubMed ID: 3801269
[TBL] [Abstract][Full Text] [Related]
50. Tumor blood flow changes induced by chemical modifiers of radiation response.
Chaplin DJ; Horsman MR
Int J Radiat Oncol Biol Phys; 1992; 22(3):459-62. PubMed ID: 1735678
[TBL] [Abstract][Full Text] [Related]
51. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
Siemann DW; Sutherland RM
Radiother Oncol; 1992 Aug; 24(4):239-45. PubMed ID: 1410579
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo.
Brown JM
Radiat Res; 1977 Dec; 72(3):469-86. PubMed ID: 594322
[No Abstract] [Full Text] [Related]
53. Metabolic rate modification of nitrotriazole radiosensitizers by sulfur substitution of side chain.
Kagiya VT; Sugita T; Nishimoto S; Masuoka M; Zhou L; Abe M; Shibamoto Y; Sasai K
Int J Radiat Oncol Biol Phys; 1992; 22(3):597-600. PubMed ID: 1735698
[TBL] [Abstract][Full Text] [Related]
54. [Radiosensitizing effect of a 2-nitroimidazole hydroxamate (KIN-804) to murine tumors].
Tada T; Nakajima T; Onoyama Y; Nagasawa H; Hori H; Inayama S
Nihon Igaku Hoshasen Gakkai Zasshi; 1992 May; 52(5):688-90. PubMed ID: 1508643
[TBL] [Abstract][Full Text] [Related]
55. TX-1877: design, synthesis, and biological activities as a BRM-functional hypoxic cell radiosensitizer.
Kasai S; Nagasawa H; Kuwasaka H; Oshodani T; Nishioka A; Ogawa Y; Yoshida S; Inayama S; Inomata T; Hori H
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):799-802. PubMed ID: 9845099
[TBL] [Abstract][Full Text] [Related]
56. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.
Olive PL
Br J Cancer; 1995 Mar; 71(3):537-42. PubMed ID: 7880736
[TBL] [Abstract][Full Text] [Related]
57. A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
Suto MJ; Stier MA; Werbel LM; Arundel-Suto CM; Leopold WR; Elliott WE; Sebolt-Leopold JS
J Med Chem; 1991 Aug; 34(8):2484-8. PubMed ID: 1875345
[TBL] [Abstract][Full Text] [Related]
58. Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
Teicher BA; Herman TS; Holden SA; Jones SM
J Natl Cancer Inst; 1989 Jun; 81(12):929-34. PubMed ID: 2525198
[TBL] [Abstract][Full Text] [Related]
59. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
60. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
